Welcome to the BioLogicTube jeo@biologicmedia.dk https://biologictube.dk/app/facebook en-us Visualplatform http://blogs.law.harvard.edu/tech/rss Welcome to the BioLogicTube episodic no https://biologictube.dk/app/facebook/files/rv0.0/sitelogo.gif https://biologictube.dk/app/facebook http://biologictube.dk/photo/53330324/interview-with-first-author-viktor <p><h1>interview on the following publication:&nbsp;</h1><p><br><a href="https://www.ncbi.nlm.nih.gov/pubmed/30885954#">Diabetes&nbsp;Care.</a>&nbsp;2019 Jun;42(6):1112-1119. doi: 10.2337/dc18-1427. Epub 2019 Mar 18.<br>Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1&nbsp;Diabetes.<br><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Rotbain%20Curovic%20V%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Rotbain Curovic V</a>1,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Theilade%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Theilade S</a>2,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Winther%20SA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Winther SA</a>2,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Tofte%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Tofte N</a>2,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Eugen-Olsen%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Eugen-Olsen J</a>3,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Persson%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Persson F</a>2,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Hansen%20TW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Hansen TW</a>2,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Jeppesen%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Jeppesen J</a>4,5,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Rossing%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Rossing P</a>2,5.<br><a href="https://www.ncbi.nlm.nih.gov/pubmed/30885954#">Author information<br></a>Abstract<br>OBJECTIVE:<br>RESEARCH DESIGN AND METHODS:<br>RESULTS:<br>CONCLUSIONS:</p><div><div></div></div><div><p>Soluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However,&nbsp;suPAR's predictive qualities for complications in type 1&nbsp;diabetes&nbsp;have yet to be determined. We investigated the prognostic value of&nbsp;suPAR&nbsp;for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1&nbsp;diabetes.</p><p>We included 667 patients with type 1&nbsp;diabetes&nbsp;with various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2-6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling of&nbsp;suPAR&nbsp;with 95% CI. Relative integrated discrimination improvement (rIDI) was calculated.</p><p>Quantification of&nbsp;suPAR&nbsp;was available in all participants; median (interquartile range) was 3.4 ng/mL (2.7-4.5). The adjusted HR (95% CI) for cardiovascular events (<i>n</i>&nbsp;= 94), progression in albuminuria (<i>n</i>&nbsp;= 36), eGFR decline (<i>n</i>&nbsp;= 93), ESRD (<i>n</i>&nbsp;= 23), and mortality (<i>n</i>&nbsp;= 58) were 3.13 (1.96-5.45,&nbsp;<i>P</i>&nbsp;&lt; 0.001), 1.27 (0.51-3.19,&nbsp;<i>P</i>&nbsp;= 0.61), 2.93 (1.68-5.11,&nbsp;<i>P</i>&nbsp;&lt; 0.001), 2.82 (0.73-11.9,&nbsp;<i>P</i>&nbsp;= 0.13), and 4.13 (1.96-8.69,&nbsp;<i>P</i>&nbsp;&lt; 0.001), respectively. rIDI was significant for cardiovascular events (22.6%,&nbsp;<i>P</i>&nbsp;&lt; 0.001), eGFR decline (14.4%,&nbsp;<i>P</i>&nbsp;&lt; 0.001), and mortality (23.9%,&nbsp;<i>P</i>&nbsp;&lt; 0.001).</p><p>In patients with type 1&nbsp;diabetes&nbsp;and a broad range of albuminuria, a higher level of&nbsp;suPAR&nbsp;is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition,&nbsp;suPAR&nbsp;contributes significantly to discrimination for the end points.</p></div></p><p><a href="http://biologictube.dk/photo/53330324/interview-with-first-author-viktor"><img src="http://biologictube.dk/49543317/53330324/ebf75c7a1044d721e5a67baff054e612/standard/download-4-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/53330324 Tue, 25 Jun 2019 14:28:33 GMT Interview with first author Viktor Curovic on his work on suPAR in diabetes... interview on the following publication:DiabetesCare.2019 Jun;42(6):1112-1119. doi: 10.2337/dc18-1427. Epub 2019 Mar 18.Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1Diabetes.Rotbain Curovic V1,Theilade S2,Winther SA2,Tofte N2,Eugen-Olsen J3,Persson F2,Hansen TW2,Jeppesen J4,5,Rossing P2,5.Author informationAbstractOBJECTIVE:RESEARCH DESIGN AND METHODS:RESULTS:CONCLUSIONS:Soluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However,suPAR's predictive qualities for complications in type 1diabeteshave yet to be determined. We investigated the prognostic value ofsuPARfor the development of cardiovascular events, decline in renal function, and mortality in patients with type 1diabetes.We included 667 patients with type 1diabeteswith various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2-6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling ofsuPARwith 95% CI. Relative integrated discrimination improvement (rIDI) was calculated.Quantification ofsuPARwas available in all participants; median (interquartile range) was 3.4 ng/mL (2.7-4.5). The adjusted HR (95% CI) for cardiovascular events (n= 94), progression in albuminuria (n= 36), eGFR decline (n= 93), ESRD (n= 23), and mortality (n= 58) were 3.13 (1.96-5.45,P 0.001), 1.27 (0.51-3.19,P= 0.61), 2.93 (1.68-5.11,P 0.001), 2.82 (0.73-11.9,P= 0.13), and 4.13 (1.96-8.69,P 0.001), respectively. rIDI was significant for cardiovascular events (22.6%,P 0.001), eGFR decline (14.4%,P 0.001), and mortality (23.9%,P 0.001).In patients with type 1diabetesand a broad range of albuminuria, a higher level ofsuPARis a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition,suPARcontributes significantly to discrimination for the end points. interview on the following publication:DiabetesCare.2019 Jun;42(6):1112-1119. doi: 10.2337/dc18-1427. Epub 2019 Mar 18.Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in... Welcome to the BioLogicTube 05:40 <p><h1>interview on the following publication:&nbsp;</h1><p><br><a href="https://www.ncbi.nlm.nih.gov/pubmed/30885954#">Diabetes&nbsp;Care.</a>&nbsp;2019 Jun;42(6):1112-1119. doi: 10.2337/dc18-1427. Epub 2019 Mar 18.<br>Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1&nbsp;Diabetes.<br><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Rotbain%20Curovic%20V%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Rotbain Curovic V</a>1,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Theilade%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Theilade S</a>2,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Winther%20SA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Winther SA</a>2,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Tofte%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Tofte N</a>2,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Eugen-Olsen%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Eugen-Olsen J</a>3,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Persson%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Persson F</a>2,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Hansen%20TW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Hansen TW</a>2,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Jeppesen%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Jeppesen J</a>4,5,&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Rossing%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30885954">Rossing P</a>2,5.<br><a href="https://www.ncbi.nlm.nih.gov/pubmed/30885954#">Author information<br></a>Abstract<br>OBJECTIVE:<br>RESEARCH DESIGN AND METHODS:<br>RESULTS:<br>CONCLUSIONS:</p><div><div></div></div><div><p>Soluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However,&nbsp;suPAR's predictive qualities for complications in type 1&nbsp;diabetes&nbsp;have yet to be determined. We investigated the prognostic value of&nbsp;suPAR&nbsp;for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1&nbsp;diabetes.</p><p>We included 667 patients with type 1&nbsp;diabetes&nbsp;with various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2-6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling of&nbsp;suPAR&nbsp;with 95% CI. Relative integrated discrimination improvement (rIDI) was calculated.</p><p>Quantification of&nbsp;suPAR&nbsp;was available in all participants; median (interquartile range) was 3.4 ng/mL (2.7-4.5). The adjusted HR (95% CI) for cardiovascular events (<i>n</i>&nbsp;= 94), progression in albuminuria (<i>n</i>&nbsp;= 36), eGFR decline (<i>n</i>&nbsp;= 93), ESRD (<i>n</i>&nbsp;= 23), and mortality (<i>n</i>&nbsp;= 58) were 3.13 (1.96-5.45,&nbsp;<i>P</i>&nbsp;&lt; 0.001), 1.27 (0.51-3.19,&nbsp;<i>P</i>&nbsp;= 0.61), 2.93 (1.68-5.11,&nbsp;<i>P</i>&nbsp;&lt; 0.001), 2.82 (0.73-11.9,&nbsp;<i>P</i>&nbsp;= 0.13), and 4.13 (1.96-8.69,&nbsp;<i>P</i>&nbsp;&lt; 0.001), respectively. rIDI was significant for cardiovascular events (22.6%,&nbsp;<i>P</i>&nbsp;&lt; 0.001), eGFR decline (14.4%,&nbsp;<i>P</i>&nbsp;&lt; 0.001), and mortality (23.9%,&nbsp;<i>P</i>&nbsp;&lt; 0.001).</p><p>In patients with type 1&nbsp;diabetes&nbsp;and a broad range of albuminuria, a higher level of&nbsp;suPAR&nbsp;is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition,&nbsp;suPAR&nbsp;contributes significantly to discrimination for the end points.</p></div></p><p><a href="http://biologictube.dk/photo/53330324/interview-with-first-author-viktor"><img src="http://biologictube.dk/49543317/53330324/ebf75c7a1044d721e5a67baff054e612/standard/download-4-thumbnail.jpg" width="600" height="338"/></a></p> Cardiovascular Diabetes diabetes complications early intervention kidney disease Peter Rossing group soluble urokinase plasminogen activator receptor suPAR suPAR and kidney type 1 diabetes